WO2004096288A3 - Método para la obtencion de minicírculos replicativos de adn para transferencia génica o como inmunomoduladores. - Google Patents

Método para la obtencion de minicírculos replicativos de adn para transferencia génica o como inmunomoduladores. Download PDF

Info

Publication number
WO2004096288A3
WO2004096288A3 PCT/CU2004/000007 CU2004000007W WO2004096288A3 WO 2004096288 A3 WO2004096288 A3 WO 2004096288A3 CU 2004000007 W CU2004000007 W CU 2004000007W WO 2004096288 A3 WO2004096288 A3 WO 2004096288A3
Authority
WO
WIPO (PCT)
Prior art keywords
minicircles
intended
gene transfer
immunomodulators
dna replication
Prior art date
Application number
PCT/CU2004/000007
Other languages
English (en)
French (fr)
Other versions
WO2004096288A2 (es
Inventor
Rodriguez Ernesto Galban
Porto Marta Gloria Duenas
Dunn Alejandro Miguel Martin
Original Assignee
Ct Ingenieria Genetica Biotech
Rodriguez Ernesto Galban
Porto Marta Gloria Duenas
Dunn Alejandro Miguel Martin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Rodriguez Ernesto Galban, Porto Marta Gloria Duenas, Dunn Alejandro Miguel Martin filed Critical Ct Ingenieria Genetica Biotech
Publication of WO2004096288A2 publication Critical patent/WO2004096288A2/es
Publication of WO2004096288A3 publication Critical patent/WO2004096288A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un método para la obtención de minicírculos replicativos de ADN con vistas a ser empleados para transferencia génica en células de organismos eucariontes con fines terapéuticos o vacunales, o como inmunomoduladores de tipo ADN. El método en cuestión permite generar los vectores mencionados a partir de hospederos bacterianos, carentes de casi cualquier secuencia no terapéutica y con las secuencias mínimas condicionales imprescindibles para su replicación.
PCT/CU2004/000007 2003-04-29 2004-04-26 Método para la obtencion de minicírculos replicativos de adn para transferencia génica o como inmunomoduladores. WO2004096288A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20030098A CU23400A1 (es) 2003-04-29 2003-04-29 Método para la obtención de minicírculos replicativos de adn para transferencia génica o como inmunomoduladores
CUCU2003/0098 2003-04-29

Publications (2)

Publication Number Publication Date
WO2004096288A2 WO2004096288A2 (es) 2004-11-11
WO2004096288A3 true WO2004096288A3 (es) 2004-12-09

Family

ID=33315384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2004/000007 WO2004096288A2 (es) 2003-04-29 2004-04-26 Método para la obtencion de minicírculos replicativos de adn para transferencia génica o como inmunomoduladores.

Country Status (2)

Country Link
CU (1) CU23400A1 (es)
WO (1) WO2004096288A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119066A2 (en) 2005-04-29 2006-11-09 The J. Craig Venter Institute Amplification and cloning of single dna molecules using rolling circle amplification
US7723077B2 (en) 2005-08-11 2010-05-25 Synthetic Genomics, Inc. In vitro recombination method
US20100008939A1 (en) * 2008-07-09 2010-01-14 General Electric Company Unprocessed rolling circle amplification product
US9125845B2 (en) * 2008-07-09 2015-09-08 General Electric Company DNA vaccines, uses for unprocessed rolling circle amplification product and methods for making the same
US8921072B2 (en) * 2008-09-02 2014-12-30 General Electric Compnay Methods to generate DNA mini-circles
WO2023205907A1 (en) * 2022-04-29 2023-11-02 Roderick Slavcev Nucleic acid delivery system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068670A1 (en) * 2001-02-26 2002-09-06 Stratagene A method for transfer of dna segments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068670A1 (en) * 2001-02-26 2002-09-06 Stratagene A method for transfer of dna segments

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIGGER B W ET AL: "AN ARAC-CONTROLLED BACTERIAL CRE EXPRESSION SYSTEM TO PRODUCE DNA MICROCIRCLE VECTORS FOR NUCLEAR AND MITOCHONDRIAL GENE THERAPY", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 25, 22 June 2001 (2001-06-22), pages 23018 - 23027, XP001121110, ISSN: 0021-9258 *
DARQUET A-M ET AL: "A NEW DNA VEHICLE FOR NONVIRAL GENE DELIVERY: SUPERCOILED MINICIRCLE", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 4, no. 12, December 1997 (1997-12-01), pages 1341 - 1349, XP001000963, ISSN: 0969-7128 *
KHAN S A: "Plasmid rolling-circle replication: Recent developments", MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, vol. 37, no. 3, August 2000 (2000-08-01), pages 477 - 484, XP002223579, ISSN: 0950-382X *

Also Published As

Publication number Publication date
WO2004096288A2 (es) 2004-11-11
CU23400A1 (es) 2009-08-04

Similar Documents

Publication Publication Date Title
WO2004087868A3 (en) Dna polymerase fusions and uses thereof
PL372107A1 (en) Over-expression of extremozyme genes in pseudomonads and closely related bacteria
WO2007014275A3 (en) Targeted integration and expression of exogenous nucleic acid sequences
SI1546322T1 (sl) Vektorji na osnovi transpozona in metode integracije nukleinskih kislin
EP1490489A4 (en) METHODS AND MEANS FOR MONITORING AND MODULATING BLOCKING A GENE
WO2003097794A3 (en) Universal-tagged oligonucleotide primers and methods of use
WO2007145612A8 (en) Paired end sequencing
AU2003252591A1 (en) Method of targeted gene disruption, genome of hyperthermostable bacterium and genome chip using the same
AU2003257013A1 (en) Methods and compositions for amplification of dna
EP1606304A4 (en) Gene expression regulating regulatory nucleotide sequences and constructs and methods thereof
NO20021223L (no) Fremgangsmater og sammensetninger for lineaer, isoterm amplifisering av polynukleotidsekvenser
WO2008067423A3 (en) Methods of improving the introduction of dna into bacterial cells
WO2004068112A3 (en) Hairpin primer amplification
WO2009010251A8 (en) Mutant dna polymerases and related methods
WO2004035760A3 (en) Complete biosynthetic gene set for biosynthesis of albicidin, resistance genes, and uses thereof
PL1608752T3 (pl) Sposób izolacji kwasów nukleinowych
WO2004031210A3 (en) Optimized multi-epitope constructs and uses thereof
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
WO2004096288A3 (es) Método para la obtencion de minicírculos replicativos de adn para transferencia génica o como inmunomoduladores.
WO2005001039A3 (en) Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
AU2003265884A1 (en) Target and method for inhibition of bacterial rna polymerase
WO2005030131A3 (en) Bis-quinazoline compounds for the treatment of bacterial infections
WO2003093428A3 (en) Gene targeting using replicating dna molecules
WO2005033265A3 (en) Optimized multi-epitope constructs and uses thereof
WO2006081463A3 (en) Thermococcus zilligii dna polymerases and variants thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase